AI summary · may contain errors
In 32 patients with HR+/HER2+ advanced breast cancer and measurable brain metastases, confirmed CNS-ORR reached 58.6% (95% CI 40.7–74.5) on palbociclib, fulvestrant, trastuzumab, and pyrotinib.
- Open access
Moving in Neuro-Oncology, Clinical Cancer Research, JAMA Neurology, Journal of Clinical Oncology, Annals of Neurology, bioRxiv, Cell Reports Medicine and Frontiers in Genetics.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In 32 patients with HR+/HER2+ advanced breast cancer and measurable brain metastases, confirmed CNS-ORR reached 58.6% (95% CI 40.7–74.5) on palbociclib, fulvestrant, trastuzumab, and pyrotinib.
AI summary · may contain errors
In a randomized phase III trial in 204 surgically treated patients with newly diagnosed brain metastases, R + TBRT markedly prolonged surgical bed recurrence outcomes versus R + SRT (HR 0.06 for time-to-SBR).
AI summary · may contain errors
In 1049 patients with renal cell carcinoma and brain metastases treated from 2016–2022, median overall survival was 20·0 months and varied widely by updated Renal GPA.
AI summary · may contain errors
Neurons are linked to many aspects of tumor biology in both brain and extracranial solid cancers, shaping growth, progression, and therapeutic resistance through bidirectional tumor–nervous system interactions.
AI summary · may contain errors
Laser interstitial thermal therapy (LITT) for brain metastases (BM) shows distinct pre-, intra-, and post-procedure imaging patterns that enable dual-baseline RANO-BM criteria for local response and progression.
AI summary · may contain errors
Radiation necrosis occurs in 4%-30% of patients with primary (glial) or metastatic brain tumors, typically emerging 6-24 months after radiotherapy.
AI summary · may contain errors
Three-fraction preoperative stereotactic radiotherapy followed by resection achieved 100% 6-month local control for resectable brain metastases in 63 treated patients.
AI summary · may contain errors
In a retrospective cohort of 66 lung adenocarcinoma patients without baseline brain metastasis, a Cox model predicts 12- and 24-month BM-free probabilities with optimism-corrected C-index 0.742.
AI summary · may contain errors
In the MDA-MB-231-BR7 mouse brain-metastasis model of triple-negative breast cancer, trastuzumab deruxtecan at 10 mg/kg reduced brain metastases by 49% versus control-ADC.
AI summary · may contain errors
An integrated single-cell and spatial transcriptomic atlas in mice shows that the early-delayed phase after irradiation compromises blood-CSF barrier integrity, linked to choroid plexus Tmsb4x+ epithelial depletion.
AI summary · may contain errors
In iFORCE, firmonertinib 160 mg once daily produced a median intracranial progression-free survival of 14.6 months in 23 EGFR-mutated NSCLC patients with brain metastases after EGFR-TKI resistance.
AI summary · may contain errors
CSF ctDNA tumor fraction detected by ultra-low-pass whole-genome sequencing in all baseline samples from seven breast cancer patients with leptomeningeal disease shows early reductions within 1–2 cycles on trastuzumab deruxtecan.
AI summary · may contain errors
Intrathecal QH104, an allogeneic B7-H3-targeted CAR γδ T-cell therapy, showed no grade ≥4 treatment-related adverse events in 3 leptomeningeal metastasis patients.
AI summary · may contain errors
Cancer-related osteoclasts in a mouse dural metastasis model disrupt meningeal lymphatic drainage, and selective osteoclast targeting restores lymphatic structure and function.
AI summary · may contain errors
A multi-cancer brain metastasis gene expression signature is consistently learned from malignant epithelial single-cell RNA-seq across six carcinoma types, achieving AUC > 0.90 for BrM prediction.
Journals this month
Topics moving, week to 17 Nov 2026
By field